The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Open accessAbstract
In recent years, chimeric antigen receptor-modified T cell (CAR T cell) therapy has proven to be a promising approach against cancer. Nonetheless, this approach still faces multiple challenges in eliminating solid tumors, one of which being the immunosuppressive tumor microenvironment (TME). Here, we demonstrated that knocking out the endogenous TGF-β receptor II (TGFBR2) in CAR T cells with CRISPR/Cas9 technology could reduce the induced Treg conversion and prevent the exhaustion of CAR T ce lls. Meanwhile, TGFBR2-edited CAR T cells had better in vivo tumor elimination efficacy, both in cell line-derived xenograft and patient-derived xenograft solid tumor models, whether administered locally or systemically. In addition, the TGFBR2-edited CAR T cells could eliminate contralaterally reinoculated xenografts in mice effectively, with an increased proportion of memory subsets within circulating CAR T cells of central memory and effector memory subsets. In conclusion, we greatly improved the in vitro and in vivo function of CAR T cells in TGF-β-rich tumor environments by knocking out endogenous TGFBR2 and propose a potentially new method to improve the efficacy of CAR T cell therapy for treating solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,809
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Guo, X., Zhang, Y., Zheng, L., Zheng, C., Song, J., Zhang, Q., Kang, B., Liu, Z., Jin, L., Xing, R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0045-3 · Cited by 1,651
Nakamura, K., Kitani, A., & Strober, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.629 · Cited by 1,594
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang, J. Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0694-x · Cited by 1,505
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Hayashi, H., Abdollah, S., Qiu, Y., Cai, J., Xu, Y.-Y., Grinnell, B. W., Richardson, M. A., Topper, J. N., Gimbrone, M. A., Wrana, J. L., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80303-7 · Cited by 1,334
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 656
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
A Rapid and General Assay for Monitoring Endogenous Gene Modification
Guschin, D. Y., Waite, A. J., Katibah, G. E., Miller, J. C., Holmes, M. C., & Rebar, E. J. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-753-2_15 · Cited by 499
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2017) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396
Self-citationCD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
Cai, G., Anumanthan, A., Brown, J. A., Greenfield, E. A., Zhu, B., & Freeman, G. J. (2008) · Nature Immunology · doi:10.1038/ni1554 · Cited by 345
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2017) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 268
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210
Wieser, R., Attisano, L., Wrana, J. L., & Massagué, J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7239-7247.1993 · Cited by 206
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., & Paulos, C. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01740 · Cited by 187
Yu, J., Wu, X., Yan, J., Yu, H., Xu, L., Chi, Z., Sheng, X., Si, L., Cui, C., Dai, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0548-2 · Cited by 184
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 162
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 150
Self-citationWieser, R., Attisano, L., Wrana, J. L., & Massagué, J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7239 · Cited by 127
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
Kosti, P., Maher, J. F., & Arnold, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01104 · Cited by 122
Sow, H. S., Ren, J., Camps, M. G. M., OSSENDORP, F. A., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 117
Adoptive T-Cell Therapy for Solid Tumors
Yeku, O., Li, X., & Brentjens, R. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_180328 · Cited by 99
The dual adverse effects of TGF-β secretion on tumor progression
Trapani, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.018 · Cited by 80
Bergan, L. A., Gross, J. A., Nevin, B., Urban, N. D., & Scholler, N. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.012 · Cited by 66
Pu, N., Zhao, G., Gao, S., Cui, Y., Xu, Y., Lv, Y., Nuerxiati, A., & Wu, W. (2018) · Central European Journal of Immunology · doi:10.5114/ceji.2018.77381 · Cited by 33
In vitro transcribed sgRNA causes cell death by inducing interferon release
Mu, W., Tang, N., Cheng, C., Sun, W. C., Wei, X., & Wang, H. (2019) · Protein & Cell · doi:10.1007/s13238-018-0605-9 · Cited by 22
Self-citation
Cited by
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Davis, M. M., Hwang, W.-T., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 533
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
Metadata
- Authors
- Tang, N., Cheng, C., Zhang, X., Qiao, M., Li, N., Mu, W., Wei, X.-F., Han, W., & Wang, H.
- Venue
- JCI Insight
- Published
- 2020-02-27
- Volume
- 5
- Issue
- 4
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W3003839508
- Cited by
- 413
- References
- 44
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.